

OFFICIALLY LICENSED

Best of ASCO®

Annual Meeting '13

[www.asco.org](http://www.asco.org)



**SLS**  
SLOVENSKÁ LEKÁRSKA SPOLOČNOSŤ

**SOLEN**  
MEDICAL EDUCATION

# Program

„Best of ASCO® event in Slovakia 2013“

Best of ASCO® event in Slovakia 2013

A program license by the American Society of Clinical Oncology

5. ročník / 5th Annual

12th October 2013 | Holiday Inn, Bratislava, Slovakia

**Place:** Holiday Inn, Bratislava, Slovakia

**Date:** 12th October 2013

**Official languages:** Slovak

---

8.00 – 8.30      **Registration**

8.30 – 8.35      **Welcome**

**President of Slovak Oncology Society, Jozef Mardiak**

## **I. Head&Neck Cancer, CNS Tumors and Melanoma Session**

**Chairmen: Dagmar Sorkovská, Pavel Dubinský**

(8.35 – 9.35)

08.35 – 08.55      **1. CNS Tumors and Head&Neck Cancer**

**(Richard Hrubý, FNŠP Žilina)**

1. Abstract #1. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). (Mark R. Gilbert)

2. Abstract #LBA2000. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial. (Ulrich Herrlinger)

3. Abstract #2001. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. (Walter Taal)

4. Abstract #2006. Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors. (Stephen R. Rapp)

5. Abstract #2003. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. (Terri S. Armstrong)

6. Abstract #4. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. (Marcia S. Brose)

7. Abstract #6009. The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. (David N. Hayes)

08.55 – 9.15

## **2. Melanoma (Zuzana Hlavatá, NOÚ Bratislava)**

1. Abstract #9003. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). (Richard D. Carvajal)
2. Abstract #9007. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (ipi) versus ipi alone in metastatic melanoma: E1608. (F. Stephen Hodi)
3. Abstract #LBA9008. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. (Robert Hans Ingemar Andtbacka)
4. Abstract #9012. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). (Jedd D. Wolchok)
5. Abstract #9009. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (1 of 3) (Antoni Ribas)
6. Abstract #9010. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2 of 3) (Omid Hamid)
7. Abstract #9011. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. (3 of 3) (Jeffrey S. Weber)

9.15 – 9.35

## **Discussion**

## **II. Breast Cancer Session**

**Chairmen: Mária Wagnerová, Stanislav Špánik**

(9.35 – 10.35)

9.35 – 9.55

## **3. Breast Cancer – Triple Negative/Cytotoxics/Local Therapy (Zuzana Syčová-Milá, NOÚ Bratislava)**

1. Abstract #1007. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. (Lawrence N. Shulman)

2. Abstract #1008. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. (G. Thomas Budd)
3. Abstract #1004. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). (Gunter Von Minckwitz)
4. Abstract #1000. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (Thomas B. Julian)
5. Abstract #LBA1001. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). (Emiel J. Rutgers)

9.55 – 10.15

**4. Breast Cancer – HER2/ER (Mária Višňovská, VOÚ Košice)**

1. Abstract #5. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. (Richard G. Gray)
2. Abstract #500. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. (Lisa A. Carey)
3. Abstract #502. ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. (Aman Buzdar)
4. Abstract #LBA509. Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2. (Gabriel N. Hortobagyi)
5. Abstract #511. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). (Fabrice Andre)

10.15 – 10.35

**Discussion**

10.35 – 11.00 Coffee-Break

### III. Genitourinary Cancer and Gynecologic Cancer Session

Chairmen: Jozef Mardiak, Igor Andrašina

(11.00 – 12.00)

11.00 – 11.20

#### 5. Genitourinary Cancer (Michal Mego, NOÚ Bratislava)

1. Abstract #4504. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). (Robert John Motzer)
2. Abstract #LBA4500. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. (Karim Fizazi)
3. Abstract #LBA4510. Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial. Prolaris: A novel genetic test for prostate cancer prognosis. (Abdenour Nabid)
4. Abstract #5009. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). (Dana E. Rathkopf)
5. Abstract #5005. Prolaris: A novel genetic test for prostate cancer prognosis. (Michael K. Brawer)

11.20 – 11.40

#### 6. Gynecologic Cancer (Juraj Beniak, POKO Poprad)

1. Abstract #3. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. (Krishnansu Sujata Tewari)
2. Abstract #5500. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. (Sean Kehoe)
3. Abstract #LBA5501. A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)– European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)–Gynecologic Cancer Intergroup (GCIG) trial. (Sandro Pignata)
4. Abstract #5505. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). (Jonathan A. Ledermann)

5. Abstract #LBA5503. *Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).* (Andreas Du Bois)

11.40 – 12.00      **Discussion**

12.00 – 13.30      **Lunch**

#### **IV. Gastrointestinal Cancer Session**

**Chairmen: Tomáš Šálek, Jozef Chovanec**

(13.30 – 14.30)

13.30 – 13.50      **7. Gastrointestinal cancer (Colorectal)**

**(Vanda Ušáková, OÚSA Bratislava)**

1. Abstract #LBA3506. *Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).* (Volker Heinemann)
2. Abstract #3505. *FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.* (Alfredo Falcone)
3. Abstract #3504. *A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.* (John Neil Primrose)
4. Abstract #3502. *Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).* (Miriam Koopman)
5. Abstract #3515. *Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.* (Christophe Tournigand)

13.50 – 14.10

**8. Gastrointestinal (Non-Colorectal) Cancer  
(Branislav Bystrický, FNŠP Trenčín)**

1. Abstract #LB4002. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. (Kazuhiro Yoshida)
2. Abstract #4023. Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. (Natalie Cook)
3. Abstract #LBA4001. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial. (J. Randolph Hecht)
4. Abstract #4008. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. (Akira Fukutomi)
5. Abstract #LB4003. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. (Pascal Hammel)
6. Abstract #LBA4004. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. (Gary William Middleton)
7. Abstract #4005. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. (Daniel D. Von Hoff)

14.10 – 14.30

**Discussion**

14.30 – 14.35

**Closing remarks**

**President of Slovak Oncology Society, Jozef Mardiak**

**FAREWELL**



**PRÍEZVISKO, MENO, TITUL (čítateľne):**

SURNAME, NAME, TITLE (legibly):

\_\_\_\_\_

**ADRESA PRACOVISKA:**

WORK ADDRESS:

\_\_\_\_\_

**TEL., FAX:**

\_\_\_\_\_

**E-MAIL:**

\_\_\_\_\_

**REG. Č. SLOVENSKEJ LEKÁRSKEJ KOMORY:**

REG. NUMBER OF THE SLOVAK MEDICAL CHAMBER:

\_\_\_\_\_

**ZÁVÄZNÁ OBJEDNÁVKA UBYTOVANIA V HOTELI HOLIDAY INN (DO 25.9.2013) / OBLIGATORY ORDER OF THE ACCOMODATION IN THE HOLIDAY INN (TO 25.9.2013)**

(Na základe vyplnenej príhlášky Vám bude obratom zaslaná zálohová faktúra na ubytovanie.)

dvojložková izba – **99 €** (cena je uvedená s DPH, zahŕňa ubytovanie na 1 noc, raňajky, miestny poplatok)

**Mám záujem o ubytovanie z 1. na 12. 10. 2013**

I would like to book a room from 1<sup>st</sup> till 12<sup>th</sup> of October 2013

áno/Yes

nie/No

**CHCEM BYŤ UBYTOVANÝ(A) S:**

I WOULD LIKE TO SHARE A ROOM WITH:

\_\_\_\_\_

Týmto dávam súhlas spoločnosti SOLENN, s.r.o. na spracovanie mojich osobných údajov, uvedených v tomto dokumente na účel spracovania príhlášok a rozosielanie informačných e-mailov v zmysle zák. č. 428/2002 Z.z. o ochrane osobných údajov. Tento súhlas je možné kedykoľvek odvolať písomnou formou.

I herein give permission to the SOLENN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of the application forms and for the distribution of information emails according to the act No. 428/2002. The act No. 428/2002 deals with security of personal data. This permission may be cancelled anytime in writing.

Rezervácia ubytovania je záväzná, zmena je možná bez účtovania storno poplatku do 25. 9. 2013. Po tomto dátume bude nautčovany 100 % storno poplatok.

V prípade záujmu, je možné uhradiť ubytovanie ubytovanie individuálne na recepcii hotela.

Reservation of the accommodation is obligatory and the changes of the reservations can be done without any fees until 25th of September 2013. After 25th of September 2013, there will be charged a 100% cancellation fee.

Vyplnenú príhlášku prosíme zaslať na adresu organizátora pošťou, mailom, faxom (02/5465 1384).

Organizátor: SOLENN, s. r. o. Lovínskeho 16, 81 1 04 Bratislava, e-mail: kongres@solenn.sk  
Please send completed Application Form to the address of the organizer by mail, email or fax (+421 2 54651384).  
Organizer: SOLENN, s. r. o., Lovínskeho 16, 81 1 04 Bratislava, e-mail: kongres@solenn.sk

Akceptujeme aj príhlášku cez web stránku spoločnosti SOLENN, s. r. o. na adrese: www.solenn.sk v sekcii Kongresy a seminare. Telefonicke príhlásenie na podujatie nie je možné. We accept the registration through the web page of organizer SOLENN, s.r.o.: www.solenn.sk in the section "Kongresy a seminare".

There is no possibility of the registration by phone.

*Podpis signature*

Príhlášky zasielajte najneskôr do **25. 9. 2013** (ubytovanie) alebo do **1. 10. 2013** (účast).

The deadline for application is 25<sup>th</sup> of September 2013 (accomodation) or 1<sup>st</sup> October 2013 (attendance).